Feasibility of high- dose targeted radiation with I131apamistamab in patients with relapsed/refractory AML: Dosimetry and radiation safety experience from the phase 3 SIERRA trial Meeting Abstract
| Authors: | Pandit-Taskar, N.; Prasad, K.; Chen, L.; Senglaub, T.; Zgaljardic, M.; Brodin, P.; Serencsits, B. |
| Abstract Title: | Feasibility of high- dose targeted radiation with I131apamistamab in patients with relapsed/refractory AML: Dosimetry and radiation safety experience from the phase 3 SIERRA trial |
| Meeting Title: | 2023 Annual Congress of the European Association of Nuclear Medicine (EANM'23) |
| Journal Title: | European Journal of Nuclear Medicine and Molecular Imaging |
| Volume: | 50 |
| Issue: | Suppl. 1 |
| Meeting Dates: | 2023 Sep 9-13 |
| Meeting Location: | Vienna, Austria |
| ISSN: | 1619-7070 |
| Publisher: | Springer |
| Date Published: | 2023-09-01 |
| Start Page: | S671 |
| End Page: | S672 |
| Language: | English |
| ACCESSION: | WOS:001084059703142 |
| PROVIDER: | wos |
| DOI: | 10.1007/s00259-023-06333-x |
| PUBMED: | 37594496 |
| Notes: | Meeting Abstract: EP-0608 -- Source: Wos |
Altmetric
Citation Impact
BMJ Impact Analytics
MSK Authors
-
345Pandit-Taskar -
11Serencsits
Related MSK Work